EA200200858A1 - Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы - Google Patents

Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы

Info

Publication number
EA200200858A1
EA200200858A1 EA200200858A EA200200858A EA200200858A1 EA 200200858 A1 EA200200858 A1 EA 200200858A1 EA 200200858 A EA200200858 A EA 200200858A EA 200200858 A EA200200858 A EA 200200858A EA 200200858 A1 EA200200858 A1 EA 200200858A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphorilase
pharmaceutical compositions
compositions containing
containing inhibitors
glycogen
Prior art date
Application number
EA200200858A
Other languages
English (en)
Inventor
Деннис Джей Хувер
Рави Майсор Шэнкер
Дуэйн Томас Фрезен
Дуглас Алан Лоренц
Джеймс Алан Шривер Найтингэйл
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200200858A1 publication Critical patent/EA200200858A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей ингибитор гликогенфосфорилазы и, по крайней мере, один повышающий концентрацию полимер, которая может представлять простую физическую смесь ингибитора гликогенфосфорилазы и повышающего концентрацию полимера или дисперсию ингибитора гликогенфосфорилазы и полимера.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200858A 2000-03-16 2001-03-16 Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы EA200200858A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
EA200200858A1 true EA200200858A1 (ru) 2003-02-27

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200858A EA200200858A1 (ru) 2000-03-16 2001-03-16 Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы

Country Status (32)

Country Link
US (1) US20010053778A1 (ru)
EP (1) EP1263414A1 (ru)
JP (1) JP2003526654A (ru)
KR (1) KR20020081445A (ru)
CN (1) CN1418089A (ru)
AP (1) AP2002002621A0 (ru)
AR (1) AR027656A1 (ru)
AU (1) AU2001242669A1 (ru)
BG (1) BG107037A (ru)
BR (1) BR0109189A (ru)
CA (1) CA2403241A1 (ru)
CO (1) CO5280087A1 (ru)
CZ (1) CZ20022955A3 (ru)
EA (1) EA200200858A1 (ru)
EE (1) EE200200530A (ru)
HU (1) HUP0204583A2 (ru)
IL (1) IL151320A0 (ru)
IS (1) IS6508A (ru)
MA (1) MA26882A1 (ru)
MX (1) MXPA02009097A (ru)
NO (1) NO20024386L (ru)
OA (1) OA12232A (ru)
PA (1) PA8513601A1 (ru)
PE (1) PE20011184A1 (ru)
PL (1) PL360780A1 (ru)
SK (1) SK12622002A3 (ru)
SV (1) SV2002000343A (ru)
TN (1) TNSN01040A1 (ru)
TR (1) TR200202184T2 (ru)
WO (1) WO2001068055A1 (ru)
YU (1) YU67202A (ru)
ZA (1) ZA200207290B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
WO2003000238A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
RS67304A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005065657A2 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森***療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
CA2917199C (en) * 2013-07-19 2021-08-31 Siga Technologies, Inc. Amorphous tecovirimat preparation
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
CA2223625C (en) * 1995-06-06 2003-06-03 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
AR027656A1 (es) 2003-04-09
OA12232A (en) 2006-05-10
MXPA02009097A (es) 2003-03-12
IL151320A0 (en) 2003-04-10
EE200200530A (et) 2004-04-15
JP2003526654A (ja) 2003-09-09
BG107037A (bg) 2003-04-30
SV2002000343A (es) 2002-07-03
WO2001068055A1 (en) 2001-09-20
ZA200207290B (en) 2003-09-11
EP1263414A1 (en) 2002-12-11
CN1418089A (zh) 2003-05-14
MA26882A1 (fr) 2004-12-20
NO20024386L (no) 2002-11-13
HUP0204583A2 (hu) 2003-04-28
CZ20022955A3 (cs) 2003-09-17
PA8513601A1 (es) 2004-08-31
TNSN01040A1 (fr) 2005-11-10
NO20024386D0 (no) 2002-09-13
US20010053778A1 (en) 2001-12-20
TR200202184T2 (tr) 2003-01-21
AU2001242669A1 (en) 2001-09-24
AP2002002621A0 (en) 2002-09-30
CA2403241A1 (en) 2001-09-20
PE20011184A1 (es) 2001-11-15
KR20020081445A (ko) 2002-10-26
YU67202A (sh) 2006-01-16
PL360780A1 (en) 2004-09-20
CO5280087A1 (es) 2003-05-30
IS6508A (is) 2002-08-16
SK12622002A3 (sk) 2004-02-03
BR0109189A (pt) 2003-05-27

Similar Documents

Publication Publication Date Title
EA200200858A1 (ru) Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы
BR0317822A (pt) Composição fluoroquìmica
EA200400980A1 (ru) Ингибиторы асс
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
EA200000433A1 (ru) Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы
DK1515702T6 (da) Misbrugssikret indgivelsesform
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
HUP9900152A2 (hu) Alkoholalapú mikrobaellenes kozmetikai készítmény és alkalmazása
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
EA200501587A1 (ru) Тонкоизмельченные предохраняющие древесину рецептуры
ATE512208T1 (de) Duftstoffkombination enthaltend 3, 7-dymethyl-6- en-nitril (citronellyl nitril) als geranonitril- substitut
ATE507822T1 (de) Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
RS20050066A (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
EA200400586A1 (ru) Замещённые тиоацетамиды
EA200702355A1 (ru) Композиции гомо- или сополимеров альфа-олефинов
BR0209149A (pt) Ftalazinonas
BR0109846A (pt) Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
BR0207826A (pt) Composições pesticidas contendo ácido oxálico
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
EA200201019A1 (ru) Антагонисты рецептора il-8